23andMe Is Mining Your DNA For The Next Big Drug. It Just Raised $250 Million
By Stephanie M. Lee,
BuzzFeed
| 09. 12. 2017
The round, led by Sequoia Capital, will help 23andMe reach more new customers and double down on its efforts to develop drugs based on customers' genetic data.
After collecting more than 2 million people’s DNA and winning hard-fought federal clearances to sell certain health tests, 23andMe has big plans — including using its customers’ genetic data to develop drugs of its own. To get there, it’s raised $250 million in a round led by powerhouse venture capital firm Sequoia Capital, the company announced today.
23andMe, which extracts genetic information about your health, ancestry, and physical traits from mail-home saliva kits, has now raised a total of $491 million. TechCrunch first reported that the company was raising its first round since 2015. The latest round’s pre-money valuation was $1.5 billion, according to Axios. (A spokesperson declined to comment on valuation.)
The new influx of capital indicates that 23andMe doesn’t plan to go public in the near future, despite launching more than a decade ago in 2006.
Under its CEO and cofounder Anne Wojcicki, the Silicon Valley startup has been working ...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
